Global Neurological Disorder Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Technology;
Imaging (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine Imaging, Positron Emission Tomography (PET), Single-photon Emission Computed Tomography (SPECT), Near Infrared Spectroscopic Imaging (NIRS), Electroencephalography (EEG), and Magnetoencephalography (MEG)) and In Vitro Diagnostics (Biomarker, Biopsy, and Others).By Disease Indication;
Genetic Neurological Disorders (Alzheimer's Disease (AD), Parkinsons Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Others), Immunological Neurological Disorders (Multiple Sclerosis and Others), Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Neurological Disorder Diagnostics Market (USD Million), 2021 - 2031
In the year 2024, the Global Neurological Disorder Diagnostics Market was valued at USD 16,995.47 million. The size of this market is expected to increase to USD 28,068.05 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.
The Global Neurological Disorder Diagnostics Market encompasses a wide array of diagnostic techniques, tools, and technologies aimed at identifying and managing various neurological conditions affecting the central and peripheral nervous systems. With neurological disorders posing significant challenges to global healthcare systems due to their complex nature and diverse manifestations, accurate and timely diagnosis is paramount for effective treatment and patient care. The introduction of innovative diagnostic modalities and advancements in neuroimaging, biomarker analysis, and genetic testing have revolutionized the field, driving the growth and evolution of the neurological disorder diagnostics market.
Neurological disorders encompass a broad spectrum of conditions, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, as well as neuropsychiatric disorders like depression, anxiety, and schizophrenia. These disorders present unique diagnostic challenges due to their heterogeneous nature, variable symptomatology, and overlapping clinical features. Healthcare providers rely on a combination of clinical assessments, imaging studies, laboratory tests, and genetic analyses to accurately diagnose and characterize neurological conditions, highlighting the multidisciplinary approach required in neurological disorder diagnostics.
The global neurological disorder diagnostics market is characterized by continuous innovation and technological advancements aimed at improving diagnostic accuracy, efficiency, and patient outcomes. Neuroimaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) play a crucial role in visualizing structural and functional abnormalities in the brain and spinal cord, aiding in the diagnosis and monitoring of neurological disorders. Additionally, the development of novel biomarkers and genetic testing methodologies enables early detection, prognostication, and personalized treatment approaches, driving the demand for advanced diagnostic tools and platforms.
The increasing prevalence of neurological disorders globally, coupled with the growing aging population and rising healthcare expenditures, fuels the demand for neurological disorder diagnostics. With neurological disorders posing significant socioeconomic burdens due to their long-term disability and healthcare costs, early and accurate diagnosis is essential for optimizing patient outcomes, reducing disease progression, and minimizing healthcare expenditures. The integration of artificial intelligence (AI) and machine learning algorithms into neurological disorder diagnostics holds immense promise for enhancing diagnostic accuracy, streamlining workflows, and facilitating precision medicine approaches tailored to individual patient profiles.
In conclusion, the global neurological disorder diagnostics market is characterized by innovation, technological advancements, and growing demand driven by the increasing prevalence of neurological disorders and the need for accurate and timely diagnosis. As healthcare systems strive to address the diagnostic challenges posed by neurological conditions, the market continues to evolve, offering opportunities for stakeholders to leverage emerging technologies and diagnostic modalities to improve patient care and outcomes in the field of neurology.
Global Neurological Disorder Diagnostics Market Recent Developments
- In May 2022, Bruker launched an innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its preclinical magnetic resonance imaging (MRI) portfolio. The new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid helium or nitrogen refills while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research.
- In April 2022, Wipro GE Healthcare launched a next-generation Revolution Aspire CT (Computed Tomography) scanner with an advanced imaging solution in India.
Segment Analysis
This report extensively covers different segments of Global Neurological Disorder Diagnostics Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
The market is segmented based on technology, disease indication, and geography, offering a comprehensive understanding of the diverse diagnostic approaches employed in identifying and managing neurological conditions worldwide. Technological segmentation in the neurological disorder diagnostics market encompasses a wide range of diagnostic modalities and tools utilized to assess various aspects of neurological function and structure. Neuroimaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) play a pivotal role in visualizing structural abnormalities, detecting lesions, and monitoring disease progression in conditions like Alzheimer's disease, stroke, and brain tumors.
The segmentation by disease indication reflects the diverse spectrum of neurological conditions addressed by diagnostic modalities in the market. Neurological disorders encompass a broad range of conditions affecting the central nervous system (CNS) and peripheral nervous system (PNS), including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, as well as neuropsychiatric disorders like depression, anxiety, bipolar disorder, and schizophrenia.
Geographic segmentation in the global neurological disorder diagnostics market provides insights into regional market dynamics, healthcare infrastructure, and disease prevalence patterns across different regions. North America and Europe dominate the market, driven by advanced healthcare systems, high disease prevalence, and robust research and development activities in neuroimaging, genetics, and biomarker analysis. The Asia Pacific region is witnessing rapid market growth fueled by the increasing prevalence of neurological disorders, improving healthcare infrastructure, and rising awareness about neurological health. Emerging economies in Latin America, the Middle East, and Africa are also experiencing market expansion, supported by government initiatives, healthcare investments, and growing disease awareness.
Global Neurological Disorder Diagnostics Segment Analysis
In this report, the Global Neurological Disorder Diagnostics Market has been segmented by Technology, Disease Indication, and Geography.
Global Neurological Disorder Diagnostics Market, Segmentation by Technology
The Global Neurological Disorder Diagnostics Market has been segmented by Technology into Imaging (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine Imaging, Positron Emission Tomography (PET), Single-photon Emission Computed Tomography (SPECT), Near Infrared Spectroscopic Imaging (NIRS), Electroencephalography (EEG), and Magnetoencephalography (MEG)) and In Vitro Diagnostics (Biomarker, Biopsy, and Others).
Imaging technologies play a pivotal role in visualizing structural and functional abnormalities in the brain and spinal cord, aiding in the diagnosis, monitoring, and treatment planning of neurological disorders. Computed tomography (CT) and magnetic resonance imaging (MRI) are widely used imaging modalities that provide detailed anatomical information and help detect lesions, tumors, hemorrhages, and other abnormalities in the brain and spinal cord. Nuclear medicine imaging techniques, including positron emission tomography (PET) and single-photon emission computed tomography (SPECT), offer functional insights by measuring metabolic activity, neurotransmitter levels, and receptor binding in the brain, facilitating the assessment of conditions such as Alzheimer's disease, epilepsy, and movement disorders. Near infrared spectroscopic imaging (NIRS) is a non-invasive imaging technique that measures changes in cerebral blood flow and oxygenation, providing real-time information about brain function and metabolism. Additionally, electroencephalography (EEG) and magnetoencephalography (MEG) are neurophysiological techniques used to record electrical activity in the brain, aiding in the diagnosis of epilepsy, sleep disorders, and other neurological conditions.
In vitro diagnostics encompass a variety of laboratory-based tests and assays performed on biological samples obtained from patients with neurological disorders. Biomarker analysis involves the measurement of specific proteins, metabolites, or genetic markers in blood, cerebrospinal fluid, or other bodily fluids, providing insights into disease pathology, progression, and treatment response. Biopsy procedures involve the extraction and examination of tissue samples from the brain, spinal cord, or peripheral nerves to diagnose conditions such as brain tumors, multiple sclerosis, and neuropathies. Other in vitro diagnostic tests may include cerebrospinal fluid analysis, genetic testing, autoimmune antibody assays, and neurochemical profiling, offering valuable diagnostic information for a wide range of neurological disorders.
Global Neurological Disorder Diagnostics Market, Segmentation by Disease Indication
The Global Neurological Disorder Diagnostics Market has been segmented by Disease Indication into Genetic Neurological Disorders (Alzheimers Disease (AD), Parkinsons Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Others), Immunological Neurological Disorders (Multiple Sclerosis and Others), Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others.
Genetic neurological disorders constitute a significant portion of the market, including conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and others. These disorders are characterized by genetic mutations or abnormalities that contribute to their pathogenesis and clinical manifestations. Diagnostic modalities for genetic neurological disorders may include genetic testing, biomarker analysis, neuroimaging, and clinical assessments to identify genetic markers, assess disease progression, and guide personalized treatment strategies.
Immunological neurological disorders represent another key segment of the market, comprising conditions such as multiple sclerosis (MS) and others. These disorders involve aberrant immune responses targeting the nervous system, leading to inflammation, demyelination, and neuronal damage. Diagnosis of immunological neurological disorders may involve cerebrospinal fluid analysis, imaging studies, autoimmune antibody assays, and neurophysiological testing to evaluate immune activity, assess disease activity, and monitor treatment response.
Paraneoplastic syndrome and paraproteinemic neuropathies are neurological manifestations associated with underlying malignancies or abnormal protein production, respectively. These conditions often present diagnostic challenges due to their diverse clinical presentations and underlying etiologies. Diagnostic approaches may include tumor marker testing, imaging studies, nerve conduction studies, and tissue biopsy to identify underlying malignancies, detect abnormal protein deposition, and assess neurological involvement.
Additionally, the category of "others" encompasses a broad spectrum of neurological conditions not classified under specific disease categories. These may include rare neurological disorders, neurodevelopmental disorders, movement disorders, neuropsychiatric conditions, and peripheral nerve disorders, among others. Diagnostic modalities for these conditions may vary depending on the underlying pathology, clinical presentation, and patient-specific factors, requiring a multidisciplinary approach involving clinical assessments, imaging studies, laboratory tests, and specialized evaluations.
Global Neurological Disorder Diagnostics Market, Segmentation by Geography
In this report, the Global Neurological Disorder Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Neurological Disorder Diagnostics Market Share (%), by Geographical Region, 2024
North America holds a significant share of the neurological disorder diagnostics market, driven by advanced healthcare systems, high disease prevalence, and robust research and development activities. The region benefits from a well-established network of diagnostic facilities, academic medical centers, and research institutions, facilitating the adoption of advanced diagnostic technologies and personalized medicine approaches. Additionally, rising healthcare expenditure, increasing awareness about neurological health, and favorable reimbursement policies contribute to market growth in North America.
Europe follows closely, with a strong presence in the neurological disorder diagnostics market fueled by sophisticated healthcare systems, high disease burden, and government initiatives to improve neurological care. Countries like Germany, the UK, France, and Italy are major contributors to the market, supported by investments in neuroimaging, genetic testing, and biomarker research. The region's aging population and increasing prevalence of neurodegenerative diseases drive the demand for diagnostic services and innovative treatment approaches.
The Asia Pacific region is experiencing rapid market growth in neurological disorder diagnostics, driven by population growth, rising disease prevalence, and improving healthcare infrastructure. Countries like China, India, Japan, and South Korea are key markets within the region, benefiting from government healthcare initiatives, increasing healthcare expenditure, and growing awareness about neurological health. The region's large patient population and expanding middle class present significant opportunities for market expansion and investment in diagnostic technologies.
The Middle East and Africa region is witnessing steady growth in the neurological disorder diagnostics market, supported by improving healthcare access, rising disease awareness, and government efforts to enhance neurological care. Countries like the United Arab Emirates, Saudi Arabia, and South Africa are leading the market in the region, driven by investments in healthcare infrastructure, medical tourism, and disease management programs. Economic challenges and healthcare disparities pose constraints to market growth in certain parts of the region.
Latin America presents a growing market for neurological disorder diagnostics, fueled by increasing healthcare investments, rising disease prevalence, and efforts to improve healthcare access and quality. Countries like Brazil, Mexico, and Argentina are key contributors to the market, supported by government initiatives, private sector investments, and partnerships with international organizations. The region's diverse population, high disease burden, and expanding healthcare infrastructure drive demand for advanced diagnostic technologies and personalized medicine approaches.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Neurological Disorder Diagnostics Market. These factors include; Market Drivers, Restraints, and Opportunities.
Drivers:
- Increasing neurological disorder prevalence
- Aging population
- Diagnostic technology advancements
-
Growing awareness of early detection importance - The growing awareness of the importance of early detection serves as a significant driver in the global neurological disorder diagnostics market. As knowledge about neurological conditions and their impact on health and well-being expands, there is a heightened recognition of the critical role that early detection plays in improving patient outcomes and quality of life. Early detection allows for timely intervention and treatment initiation, which can help mitigate disease progression, prevent complications, and enhance treatment efficacy.
One of the key factors driving the awareness of early detection importance is the increasing prevalence of neurological disorders globally. With conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis affecting millions of individuals worldwide, there is a growing sense of urgency to identify these conditions at the earliest stages when interventions are most effective. Public health campaigns, patient advocacy groups, and healthcare providers play pivotal roles in raising awareness about the signs and symptoms of neurological disorders and the importance of seeking timely medical evaluation for early diagnosis.
Advancements in diagnostic technologies and screening tools have contributed to the growing awareness of early detection importance. Innovations in neuroimaging techniques, biomarker analysis, and genetic testing enable healthcare providers to detect neurological abnormalities and disease markers with greater sensitivity and specificity, even before the onset of clinical symptoms. This early detection capability empowers healthcare professionals to implement preventive measures, initiate appropriate treatments, and monitor disease progression more effectively, ultimately improving patient outcomes and reducing healthcare costs associated with advanced disease stages.
Additionally, the shift towards patient-centered care and personalized medicine has underscored the importance of early detection in tailoring treatment approaches to individual patient needs. By identifying neurological conditions at early stages, healthcare providers can develop personalized treatment plans based on the specific characteristics of each patient's disease, genetic profile, and clinical presentation. This precision medicine approach not only improves treatment outcomes but also minimizes the risk of adverse effects and enhances patient satisfaction with their care.
In conclusion, the growing awareness of the importance of early detection is driving advancements in neurological disorder diagnostics and transforming clinical practice. By recognizing the value of early intervention and proactive screening initiatives, healthcare systems, policymakers, and advocacy organizations are working together to promote early detection strategies, improve access to diagnostic services, and empower individuals to take control of their neurological health. As a result, early detection is poised to remain a critical driver in the global fight against neurological disorders, shaping the future of neurological care and patient outcomes worldwide.
Restraints:
- Limited accessibility in some regions
- Regulatory barriers
- Shortage of skilled professionals
-
Biomarker standardization challenges - Biomarker standardization challenges represent a notable restraint in the global neurological disorder diagnostics market. Biomarkers play a crucial role in the early detection, diagnosis, and monitoring of neurological conditions by providing measurable indicators of biological processes or disease states. The lack of standardized protocols for biomarker identification, validation, and measurement poses significant challenges to their effective implementation in clinical practice.
One of the key challenges associated with biomarker standardization is the variability in assay techniques and measurement platforms used across different laboratories and diagnostic centers. Without standardized methods for sample collection, processing, and analysis, biomarker measurements may yield inconsistent results, hindering the reproducibility and reliability of diagnostic tests. This variability not only complicates the interpretation of biomarker data but also limits the comparability of results between studies and patient populations.
The lack of validated reference materials and quality control standards further exacerbates biomarker standardization challenges. Biomarker assays often rely on calibration standards, reference materials, and quality control samples to ensure accuracy, precision, and reliability. The availability of well-characterized reference materials for neurological biomarkers remains limited, making it difficult to establish common reference values and assay performance criteria across different laboratories and diagnostic platforms.
Opportunities:
- Neuroimaging, biomarker tech innovation
- Point-of-care diagnostics growth
- Wearable device adoption
- Screening, early detection programs
-
Neurodiagnostics startup investments - Neurodiagnostics startup investments present a promising opportunity in the global neurological disorder diagnostics market. The emergence of innovative startups focused on developing novel diagnostic technologies, digital health solutions, and data analytics platforms for neurological disorders has attracted significant interest from investors seeking to capitalize on the growing demand for advanced diagnostic tools and personalized medicine approaches in neurology.
One of the key opportunities offered by neurodiagnostics startup investments is the potential for disruptive innovation and technological advancement in the field. Startups often bring fresh perspectives, agile development processes, and interdisciplinary expertise to the table, enabling them to explore new approaches to neurodiagnostics that may not be feasible within larger, more established companies. By leveraging technologies such as artificial intelligence, machine learning, wearable devices, and remote monitoring solutions, neurodiagnostics startups can develop next-generation diagnostic tools that offer enhanced sensitivity, specificity, and usability compared to traditional diagnostic modalities.
Neurodiagnostics startup investments facilitate collaboration and knowledge exchange among industry stakeholders, academia, and healthcare providers, fostering a vibrant ecosystem of innovation and entrepreneurship in neurology. By partnering with leading research institutions, clinical experts, and patient advocacy groups, startups can access valuable resources, clinical data, and patient insights to inform the development and validation of their diagnostic technologies. This collaborative approach not only accelerates the translation of scientific discoveries into clinical applications but also enhances the relevance and impact of neurodiagnostics innovations in real-world settings.
Competitive Landscape Analysis
Key players in Global Neurological Disorder Diagnostics Market include,
- Siemens Healthineers
- GE Healthcare
- Philips Healthcare
- Hitachi Medical Systems
- Fujifilm Holdings Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- PerkinElmer, Inc.
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Bruker Corporation
- Hologic, Inc.
- QIAGEN N.V.
- Becton, Dickinson and Company
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Disease Indication
- Market Snapshot, By Region
- Global Neurological Disorder Diagnostics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing neurological disorder prevalence
- Aging population
- Diagnostic technology advancements
- Growing awareness of early detection importance
- Restraints
- Limited accessibility in some regions
- Regulatory barriers
- Shortage of skilled professionals
- Biomarker standardization challenges
- Opportunities
- Neuroimaging, biomarker tech innovation
- Point-of-care diagnostics growth
- Wearable device adoption
- Screening, early detection programs
- Neurodiagnostics startup investments
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Neurological Disorder Diagnostics Market, By Technology, 2021 - 2031 (USD Million)
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- Biomarker
- Biopsy
- Others
- Imaging
- Global Neurological Disorder Diagnostics Market, By Disease Indication, 2021 - 2031 (USD Million)
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- Genetic Neurological Disorders
- Global Neurological Disorder Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Neurological Disorder Diagnostics Market, By Technology, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Siemens Healthineers
- GE Healthcare
- Philips Healthcare
- Hitachi Medical Systems
- Fujifilm Holdings Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- PerkinElmer, Inc.
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Bruker Corporation
- Hologic, Inc.
- QIAGEN N.V.
- Becton, Dickinson and Company
- Company Profiles
- Analyst Views
- Future Outlook of the Market